Headache and Migraine

In addition to increased risk of dementia, focal epilepsy was associated with widespread structural brain change reflected by lower total hippocampal and total gray matter volume.

Neurology News Network for the week ending May 6, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 5, 2023.

The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]

Presented at the 2023 AAN Annual Meeting, remote electrical neuromodulation demonstrated itself as an effective and safe treatment for the prevention of migraine when applied every other day.

A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.

A statistically significantly higher proportion of patients, both with and without predose aura, achieved 2-hour relief of the most bothersome symptom with zavegepant.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending April 30, 2023. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 28, 2023.

The president elect of the Association of University Professors of Neurology discussed the benefits of working in neurology and the ways to not only attract new clinicians, but keep those already in the field. [WATCH TIME: 3 minutes]

In comparison with placebo, atogepant 30 mg twice daily and 60 mg once daily resulted in greater reductions in monthly migraine days, as well as proportion of patients with at least 50% reduction in 3-month average of MMDs.

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

A greater proportion of patients on ubrogepant reported absence of moderate-to-severe intensity headache within 48 hours, ability to function normally, and absence of headache of any intensity.

Findings showed a significant reduction in mean monthly migraine days with atogepant 60 mg once daily for patients with episodic migraine compared with placebo across a 12-week period.

Zavegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, provided onset of pain relief as early as 15 minutes postdose and sustained benefits to 48 hours post dose.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 21, 2023.

Collectively, the results suggested that multiple sclerosis and migraine may co-occur because they share several genetic variants, rather than migraine causing MS.

AbbVie’s oral calcitonin gene-related peptide receptor antagonist, marketed as Qulipta, is now approved for both chronic and episodic migraine. The FDA's decision was supported by data from the PROGRESS trial.

In a study of more than 1500 adolescents, two-thirds of individuals experienced relief from functional disability with Nerivio.

The oral treatment, marketed as Rizafilm, is a disintegrating film formulation of the 5-HT1 receptor agonist and is bioequivalent to Merck’s Maxalt-MLT.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 14, 2023.

Compared with children without posttraumatic headache, those who experienced migraine symptoms following concussion were nearly 3 times more likely to report reliable increases in somatic symptoms.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis (MS).